biostudies-literatureUnknown9(97)Ahlmanner FIncreasing knowledge of the function and regulation of tumor-infiltrating lymphocytes has led to new insights in cancer immunotherapy. Regulatory T cells (Treg) accumulate in colon tumors, and we recently showed that CD39⁺ Treg from cancer patients inhibit transendothelial migration of conventional T cells. CD39 mediates the hydrolysis of ATP to immunosuppressive adenosine and adds to the immunosuppressive effects of Treg. Here, we further investigated the regulatory features of intratumoral CD39⁺ Treg in colon cancer. Using flow cytometry analyses of cells from 46 colon cancer patients, we confirm the accumulation of CD39⁺ Treg in the tumor tissue compared to unaffected colon tissue, and also show that tumor-infiltrating Treg express more CD39 and Foxp3 onOncotarget36993-37007https://www.ebi.ac.uk/biostudies/studies/S-EPMC6319332biostudies-literatureCD39⁺ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function.PMC6319332Borjesson LGustavsson BAkeus PAhlmanner FQuiding-Jarbrink MSundstrom PLindskog EBEklof JRaghavan SfalseCD39⁺ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function.Increasing knowledge of the function and regulation of tumor-infiltrating lymphocytes has led to new insights in cancer immunotherapy. Regulatory T cells (Treg) accumulate in colon tumors, and we recently showed that CD39⁺ Treg from cancer patients inhibit transendothelial migration of conventional T cells. CD39 mediates the hydrolysis of ATP to immunosuppressive adenosine and adds to the immunosuppressive effects of Treg. Here, we further investigated the regulatory features of intratumoral CD39⁺ Treg in colon cancer. Using flow cytometry analyses of cells from 46 colon cancer patients, we confirm the accumulation of CD39⁺ Treg in the tumor tissue compared to unaffected colon tissue, and also show that tumor-infiltrating Treg express more CD39 and Foxp3 on2018-01-01T00:00:00Z2018 Dec2025-04-18T14:30:00.385Z2019-03-26T22:37:34ZS-EPMC63193323065193010.18632/oncotarget.26435